Cardiokine Inc. is getting $50 million up front in a potential $220 million deal with Biogen Idec Inc. covering the vasopressin receptor antagonist lixivaptan. (BioWorld Today)

Cardiokine Inc. is getting $50 million up front in a potential $220 million deal with Biogen Idec Inc. covering the vasopressin receptor antagonist lixivaptan. (BioWorld Today)

Serenex Inc. raised $31 million in Series D and debt funding to advance its lead compound for treating oral mucositis and the Hsp90 inhibitors behind that in the pipeline. (BioWorld Today)

Serenex Inc. raised $31 million in Series D and debt funding to advance its lead compound for treating oral mucositis and the Hsp90 inhibitors behind that in the pipeline. (BioWorld Today)